natgillin/translations-raw huggingface dataset:
If Fournier´s gangrene is suspected, Synjardy should be discontinued and prompt treatment (including antibiotics and surgical debridement) should be instituted. 
Če obstaja sum na Fournierovo gangreno, je treba zdravilo Synjardy ukiniti in uvesti takojšnje zdravljenje (vključno z antibiotiki in kirurško odstranitvijo prizadetega tkiva).
It is unknown if this medicine is harmful to the unborn child. 
Ni znano, ali zdravilo Synjardy škoduje nerojenemu otroku.
It does not stimulate insulin secretion and therefore does not produce hypoglycaemia. 
Ne stimulira izločanja insulina in tako ne povzroča hipoglikemije.
It is assumed that the pharmacokinetics of metformin absorption are non-linear. 
Domneva se, da je farmakokinetika absorpcije metformina nelinearna.
Contact a doctor or the nearest hospital straight away if you have any of the following side effects: 
Nemudoma se obrnite na zdravnika ali najbližjo bolnišnico, če opazite katerega od naslednjih neželenih učinkov:
It is important that you continue with your diet and exercise plan as told by your doctor, pharmacist or nurse. 
Pomembno je, da nadaljujete z dieto in telesno aktivnostjo, kot vam je naročil zdravnik, farmacevt ali medicinska sestra.
If you have reduced kidney function, your doctor may prescribe a lower dose. 
Če imate zmanjšano delovanje ledvic, vam bo morda zdravnik predpisal manjši odmerek.
In the EMPA-REG OUTCOME study, 10.1% of the patients were reported with cardiac failure at baseline. 
V študiji EMPA-REG OUTCOME so pri 10,1 % bolnikih poročali o srčnem popuščanju v izhodišču študije.
See subsections below for additional information 
Za dodatne informacije glejte spodnja podpoglavja.
The tablet is 19.2 mm long and has a width of 9.4 mm. 
Tableta je dolga 19,2 mm in široka 9,4 mm.
Based on in vitro studies, empagliflozin is considered unlikely to cause interactions with medicinal products that are P-gp substrates. 
Na podlagi študij in vitro ni verjetno, da bi empagliflozin povzročil medsebojno delovanje z zdravili, ki so substrati P-gp.
Animal studies with empagliflozin and metformin do not indicate direct or indirect harmful effects with respect to fertility (see section 5.3). 
Študije na živalih z empagliflozinom in metforminom ne kažejo neposrednih ali posrednih škodljivih učinkov na plodnost (glejte poglavje 5.3).
The frequency of reported nocturia was comparable between placebo and empagliflozin (<1%). 
Pogostnost, s katero so poročali o nokturiji, je bila primerljiva pri placebu in empagliflozinu (< 1 %).
• corticosteroids (given by mouth, as an injection, or inhaled), which are used to treat inflammation in diseases like asthma and arthritis. 
• kortikosteroide (peroralne, inhalacijske ali v obliki injekcij), ki se uporabljajo za zdravljenje vnetij pri boleznih, kot sta astma in artritis;
Like for all diabetic patients it is important to counsel patients on routine preventative footcare. 
Kot pri vseh bolnikih s sladkorno boleznijo je pomembno, da jih podučimo o rutinski preventivni negi stopal.
Due to the mechanism of action, decreased renal function will result in reduced glycaemic efficacy of empagliflozin. 
Zaradi mehanizma delovanja bo zmanjšano delovanje ledvic povzročilo zmanjšano glikemično učinkovitost empagliflozina.
Your doctor may want to lower the dose of these other medicines, to prevent your blood sugar levels from getting too low (hypoglycaemia). 
Vaš zdravnik bo morda zmanjšal odmerek teh zdravil, da prepreči pojav prenizke ravni krvnega sladkorja (hipoglikemija);
The tablet is 21.1 mm long and has a width of 9.7 mm. 
Tableta je dolga 21,1 mm in široka 9,7 mm.
Synjardy is contraindicated in patients with GFR<30 ml/min and should be temporarily discontinued in the presence of conditions that alter renal function, see section 4.3. 
Synjardy je kontraindiciran pri bolnikih z GFR< 30 ml/min in ga je treba začasno ukiniti, če se pojavijo stanja, ki spremenijo delovanje ledvic, glejte poglavje 4.3.
Both doses provided similar statistically significant reductions in body weight, expressed as kg and percentage change. 
Pri obeh odmerkih je bilo opaženo podobno statistično značilno zmanjšanje telesne mase s spremembo, izraženo v kilogramih in odstotni vrednosti.
• passing more urine than usual or needing to pass urine more often 
• večje količine seča od običajnih ali potreba po pogostejšem uriniranju,
These symptoms could be a sign of a rare but serious or even life-threatening infection, called necrotising fasciitis of the perineum or Fournier´s gangrene which destroys the tissue under the skin. 
Ti simptomi so lahko znak redke, vendar resne ali celo življenjsko nevarne okužbe, ki se imenuje nekrotizirajoči fasciitis presredka ali Fournierova gangrena, ki uniči tkivo pod kožo.
Because metformin is excreted by the kidney and elderly patients are more likely to have decreased renal function, Synjardy should be used with caution in these patients. 
Ker se metformin izloča skozi ledvice in ker je pri starejših bolnikih večja verjetnost za zmanjšano delovanje ledvic, je treba zdravilo Synjardy pri tej skupini bolnikov uporabljati previdno.
Some responses were increased by the combination treatment, such as effects on renal physiology, electrolyte balance and acid/base state. 
Zdravljenje s kombinacijo je povečalo določene učinke, kot so učinki na fiziologijo ledvic, elektrolitsko ravnovesje in kislinsko-bazično ravnovesje.
• pain in the pelvis, or mid-back pain (when kidneys are infected) 
• bolečina v predelu medenice ali sredine hrbta (če so okužene ledvice).
These may be medicines taken by mouth or given by injection such as insulin. 
To so lahko zdravila, ki se jemljejo peroralno (se zaužijejo) ali pa se jih injicira, tako kot insulin.
Food decreases the extent and slightly delays the absorption of metformin. 
Hrana zmanjša obseg absorpcije metformina in jo nekoliko upočasni.
SGLT2 prevents glucose (blood sugar) from being lost in urine by absorbing glucose back into the bloodstream as blood is being filtered in the kidneys. 
SGLT2 preprečuje izgubo glukoze (krvnega sladkorja) v urinu, tako da absorbira glukozo nazaj v krvni obtok, medtem ko se kri filtrira v ledvicah.
The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment with such medicinal products. 
Bolnika je treba s tem seznaniti in zlasti na začetku zdravljenja s temi zdravili pogosteje spremljati raven glukoze v krvi.
Necrotising fasciitis of the perineum (Fournier´s gangrene) 
nekrotizira joči fasciitis presredka (Fourniero va gangrena)
What Synjardy is and what it is used for 
Kaj je zdravilo Synjardy in za kaj ga uporabljamo
You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dosage of Synjardy. 
Morda boste morali pogosteje opravljati preiskave glukoze v krvi in delovanja ledvic, zdravnik pa bo morda moral prilagoditi odmerek zdravila Synjardy.
Renal clearance of metformin is >400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion. 
Ledvični očistek metformina je > 400 ml/min, kar nakazuje, da se metformin izloča z glomerulno filtracijo in tubulno sekrecijo.
Synjardy can also be combined with other medicines for the treatment of diabetes. 
Zdravilo Synjardy se lahko uporablja tudi v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni.
2 hour post-prandial glucose 
Vrednost glukoze 2 uri po jedi
No Met 
Brez Met
Hypoglycaemia has not been seen with metformin doses of up to 85 g, although lactic acidosis has occurred in such circumstances. 
Pri odmerkih metformina do 85 g niso zasledili hipoglikemije, vendar se je pri takih primerih pojavila laktacidoza.
• Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: decompensated heart failure, respiratory failure, recent myocardial infarction, 
• Bolezni, ki lahko povzročijo tkivno hipoksijo (predvsem akutne bolezni ali poslabšanje kroničnih bolezni), kot so: dekompenzirano srčno popuščanje, odpoved dihal, nedavni miokardni infarkt, šok.
Metformin increases the transport capacity of all types of membrane glucose transporters (GLUTs) known to date. 
Metformin poveča sposobnost prenosa vseh doslej znanih membranskih prenašalcev glukoze (GLUT, glucose transporter).
No interaction studies have been performed for Synjardy. 
Študij medsebojnega delovanja za zdravilo Synjardy niso izvedli.
The population pharmacokinetic analysis showed that the apparent oral clearance of empagliflozin decreased with a decrease in creatinine clearance leading to an increase in drug exposure. 
Populacijska farmakokinetična analiza je pokazala, da se je navidezni peroralni očistek empagliflozina zmanjšal z zmanjšanjem kreatininskega očistka, kar je povzročilo večjo izpostavljenost zdravilu.
Therefore, caution should be exercised in patients for whom a empagliflozin-induced drop in blood pressure could pose a risk, such as patients with known cardiovascular disease, patients on anti-hypertensive therapy with a history of hypotension or patients aged 75 years and older. 
Zato je potrebna previdnost pri bolnikih, pri katerih lahko znižanje krvnega tlaka, ki ga povzroči empagliflozin, predstavlja tveganje, kot so bolniki z znano boleznijo srca in ožilja, bolniki s hipotenzijo v anamnezi, ki se zdravijo z antihipertenzivi; ali bolniki, stari 75 let ali več.
Thereafter, eGFR was maintained during continued treatment. 
V nadaljevanju zdravljenja se je vrednost eGFR ohranila.
For metformin, AUC decreased by 12% and Cmax decreased by 26% compared to fasting conditions. 
Za metformin se je vrednost AUC zmanjšala za 12 %, vrednost Cmax pa za 26 % v primerjavi s stanjem na tešče.
The following statements reflect the pharmacokinetic properties of the individual active substances of Synjardy. 
Spodnje trditve temeljijo na farmakokinetičnih lastnostih posameznih zdravilnih učinkovin zdravila Synjardy.
Taking this medicine in combination with medicines called sulphonylureas or with insulin can cause blood sugar levels to drop too low (hypoglycaemia), which may cause symptoms such as shaking, sweating and change in vision, and may affect your ability to drive and use machines. 
Jemanje tega zdravila skupaj z zdravili, imenovanimi sulfonilsečnine, ali z insulinom lahko povzroči znižanje ravni krvnega sladkorja (hipoglikemijo), ki lahko povzroči simptome, kot so tresenje, znojenje in spremembe vida, in lahko vpliva na vašo sposobnost vožnje in upravljanja s stroji.
The mean age was 63 years, the mean HbA1c was 8.1%, and 71.5% were male. 
Povprečna starost bolnikov je bila 63 let, povprečna vrednost HbA1c 8,1 %, 71,5 % bolnikov je bilo moških.
Your doctor may prescribe Synjardy together with another diabetes medicine. 
Zdravnik vam lahko predpiše zdravilo Synjardy skupaj z drugim antidiabetičnim zdravilom.
In patients with type 2 diabetes, urinary glucose excretion increased immediately following the first dose of empagliflozin and is continuous over the 24 hour dosing interval. 
Pri bolnikih s sladkorno boleznijo tipa 2 se je izločanje glukoze z urinom povečalo takoj po prvem odmerku empagliflozina in je ostalo v 24-urnem intervalu odmerjanja stalno.
Drug-drug interactions involving the major CYP450 and UGT isoforms with empagliflozin and concomitantly administered substrates of these enzymes are therefore considered unlikely. 
Zato medsebojno delovanje, pri katerem sodelujejo glavne izooblike CYP450 in UGT, med empagliflozinom in sočasno uporabljenimi substrati teh encimov ni verjetno.
The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes. 
Metformin V prospektivni randomizirani študiji (UKDPS) je bila dokazana dolgoročna korist intenzivnega urejanja glukoze v krvi pri sladkorni bolezni tipa 2.
Based on the mode of action of SGLT2 inhibitors, osmotic diuresis accompanying therapeutic glucosuria may lead to a modest decrease in blood pressure (see section 5.1). 
Na podlagi načina delovanja zaviralcev SGLT2 lahko osmotska diureza, ki spremlja terapevtsko glukozurijo, povzroči zmerno znižanje krvnega tlaka (glejte poglavje 5.1).
Other side effects while taking Synjardy: Very common 
Drugi neželeni učinki, ki se lahko pojavijo med jemanjem zdravila Synjardy: Zelo pogosti:
• Take the tablets with meals to lower your chance of an upset stomach. 
• Tablete zaužijte ob jedi, da zmanjšate možnost pojava želodčnih težav.
Lactic acidosis Vitamin B12 deficiency 
žeja diabetična ketoacidoza laktacidoza pomanjkanje vitamina B12
• blood tests may show changes in blood fat (cholesterol) levels in your blood 
• krvni testi lahko pokažejo spremembe ravni maščob v krvi (holesterol).
Synjardy should be taken twice daily with meals to reduce the gastrointestinal adverse reactions associated with metformin. 
Zdravilo Synjardy je treba jemati dvakrat dnevno med jedjo, da bi zmanjšali z metforminom povezane neželene učinke na prebavila.
Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs, ATC code: A10BD20 
Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa, kombinacije peroralnih antidiabetikov, oznaka ATC: A10BD20
C]-empagliflozin solution to healthy volunteers, approximately 96% of the drug-related radioactivity was eliminated in faeces (41%) or urine (54%). 
Po peroralnem zaužitju raztopine C]-empagliflozina se je pri zdravih prostovoljcih približno 96 % radioaktivnosti, povezane z zdravilom, izločilo v blato (41 %) ali urin (54 %).
For patients with acute and unstable heart failure, Synjardy is contraindicated due to the metformin component (see section 4.3). 
Pri bolnikih z akutnim in nestabilnim srčnim popuščanjem je zdravilo Synjardy kontraindicirano, ker vsebuje metformin (glejte poglavje 4.3)
Empagliflozin is a substrate of the human uptake transporters OAT3, OATP1B1, and OATP1B3, but not OAT1 and OCT2. 
Empagliflozin je substrat humanih privzemnih prenašalcev OAT3, OATP1B1 in OATP1B3, ne pa tudi OAT1 in OCT2.
What you need to know before you take Synjardy 
Kaj morate vedeti, preden boste vzeli zdravilo Synjardy
Stop taking Synjardy for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. 
Za kratek čas prenehajte jemati zdravilo Synjardy, če imate stanje, ki je lahko povezano z dehidracijo (znatna izguba telesnih tekočin), kot je hudo bruhanje, driska, zvišana telesna temperatura, izpostavljenost vročini ali če pijete manj tekočine, kot običajno.
Your doctor may decide to temporarily or permanently stop your treatment with Synjardy. 
Zdravnik se lahko odloči za začasno ali dokončno prekinitev zdravljenja z zdravilom Synjardy.
If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example in the context of an X-ray or scan, you must stop taking Synjardy before or at the time of the injection. 
Če vam bodo v krvni obtok injicirali kontrastno sredstvo, ki vsebuje jod, na primer zaradi rentgenskega ali drugega slikanja, morate pred časom injiciranja ali v tem času prenehati z jemanjem zdravila Synjardy.
At the recommended metformin doses and dosing schedules, steady-state plasma concentrations are reached within 24 to 48 hours and are generally less than 1 microgram/ml. 
Pri uporabi priporočenih odmerkov in shem odmerjanja doseže metformin koncentracijo v stanju dinamičnega ravnovesja v plazmi v 24 do 48 urah, in je na splošno manjša od 1 mikrograma/ml.
Empagliflozin and metformin 
Empagliflozin in metformin
• blood tests may show changes related to kidney function (creatinine or urea) 
• krvni testi lahko pokažejo spremembe, povezane z delovanjem ledvic (kreatinin ali sečnina);
Table 2: Tabulated list of adverse reactions (MedDRA) from placebo-controlled studies and from post-marketing experience 
Preglednica 2: Tabelarični pregled neželenih učinkov (MedDRA), o katerih so poročali pri s placebom nadzorovanih študijah in na osnovi izkušenj v obdobju trženja
Synjardy with alcohol 
Zdravilo Synjardy skupaj z alkoholom
For patients insufficiently controlled on metformin (either alone or in combination with other medicinal products for the treatment of diabetes) 
Pri bolnikih z nezadostno urejeno boleznijo pri jemanju metformina (v monoterapiji ali v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni)
Lactic acidosis, seen very rarely (may affect up to 1 in 10,000 people) Synjardy may cause a very rare but very serious side effect called lactic acidosis (see section ‘Warnings and precautions'). 
Laktacidoza, zelo redka (pojavi se lahko pri največ 1 od 10.000 bolnikov) Zdravilo Synjardy lahko povzroči zelo redek, a zelo resen neželeni učinek, imenovan laktacidoza (glejte poglavje "Opozorila in previdnostni ukrepi").
At 78 weeks, the decrease in HbA1c and insulin sparing effect of empagliflozin was maintained. 
V 78. tednu se je zmanjšanje vrednosti HbA1c in varčevanje z insulinom zaradi empagliflozina ohranilo.
Compared to linagliptin 5 mg, both doses of empagliflozin plus linagliptin 5 mg provided statistically significant reductions in FPG and blood pressure. 
V primerjavi z linagliptinom 5 mg sta oba odmerka empagliflozina z linagliptinom 5 mg nadalje povzročila statistično značilno zmanjšanje vrednosti FPG in krvnega tlaka.
The mode of action for these tumours is dependent on the natural predisposition of the male mouse to renal pathology and a metabolic pathway not reflective of humans. 
Mehanizem delovanja pri teh tumorjih je odvisen od naravne nagnjenosti mišjih samcev k boleznim ledvic in presnovne poti, ki pri človeku ni prisotna.
• if you have a severe infection such as an infection affecting your lung or bronchial system or your kidney. 
• če imate hudo okužbo, kot je okužba, ki prizadene pljuča, bronhije ali ledvice.
Your doctor may ask you to stop taking Synjardy until you have recovered. 
Vaš zdravnik vam bo morda naročil, da zdravilo Synjardy prenehate jemati, dokler ne okrevate.
Most toxicity was consistent with secondary pharmacology related to urinary glucose loss and electrolyte imbalances including decreased body weight and body fat, increased food consumption, diarrhoea, dehydration, decreased serum glucose and increases in other serum parameters reflective of increased protein metabolism and gluconeogenesis, urinary changes such as polyuria and glucosuria, and microscopic changes including mineralisation in kidney and some soft and vascular tissues. 
Toksičnost je bila povečini skladna s sekundarno farmakologijo, povezano z izgubo glukoze z urinom, in neravnovesjem elektrolitov, vključno z zmanjšanjem telesne mase in telesne maščobe, povečanim uživanjem hrane, drisko, dehidracijo, zmanjšanjem glukoze v serumu in povečanjem drugih serumskih parametrov, ki so posledica večje presnove beljakovin in glukoneogeneze, spremembami urina, kot so poliurija in glukozurija, in mikroskopskimi spremembami, vključno z mineralizacijo v ledvicah ter delno v mehkem in žilnem tkivu.
These symptoms could be a sign of “diabetic ketoacidosis”a rare, but serious, sometines life-threatening problem you can get with diabetes because of increased levels of “ketone bodies” in your urine or blood, seen in tests. 
Ti simptomi so lahko znak “diabetične ketoacidoze”, redke, vendar resne in včasih življenjsko nevarne težave, ki se lahko pojavi pri sladkorni bolezni zaradi povišanih ravni “ketonskih teles” v urinu ali krvi, kar je razvidno iz laboratorijskih preiskav.
Body Weight (kg) at week 52 
Telesna masa (kg) v 52. tednu
• if you have lost a lot of water from your body (dehydration), e.g. due to long-lasting or severe diarrhoea, or if you have vomited several times in a row. 
• če ste izgubili veliko vode (dehidracija), npr. zaradi dolgotrajne ali hude driske ali večkratnega zaporednega bruhanja.
• shaking, sweating, feeling very anxious or confused, fast heart beat 
• tresenje, znojenje, občutek tesnobe ali zmedenosti, hiter srčni utrip;
The inter-subject and residual variabilities for empagliflozin oral clearance were 39.1% and 35.8%, respectively. 
Za peroralni očistek je bila variabilnost empagliflozina med posamezniki 39,1 %, rezidualna variabilnost pa 35,8 %.
• if you have severely reduced kidney function; 
• če imate hudo oslabljeno delovanje ledvic,
The amount of glucose removed by the kidney through this glucuretic mechanism is dependent on blood glucose concentration and GFR. 
Količina glukoze, ki jo ledvice izločijo s pomočjo tega glukuretičnega mehanizma, je odvisna od koncentracije glukoze v krvi in hitrosti glomerulne filtracije (GFR).
No Met mg mg 
+ Met mg mg
After oral administration, empagliflozin was rapidly absorbed with peak plasma concentrations occurring at a median tmax of 1.5 hours post-dose. 
Po peroralnem jemanju se je empagliflozin hitro absorbiral in dosegel največjo koncentracijo v plazmi z medianim tmax 1,5 ure po odmerku.
Similar results were obtained when Synjardy (empagliflozin/metformin) combination tablets were administered with high-fat and high calorie meal. 
Rezultati so bili podobni pri dajanju kombiniranih tablet Synjardy (empagliflozin/metmorfin) sočasno z obrokom z visoko vsebnostjo maščob in kalorij.
• medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as ibuprofen and celecoxib). 
• zdravila za zdravljenje bolečine in vnetja (nesteroidna protivnetna zdravila in ali zaviralci COX2, kot sta ibuprofen in celekoksib),
• Metformin works in a different way to lower blood sugar levels, mainly by blocking glucose production in the liver. 
• Metformin ima drugačen mehanizem zniževanja ravni krvnega sladkorja, ki pretežno vključuje zaviranje nastajanja glukoze v jetrih.
Synjardy may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly. 
Zdravilo Synjardy lahko povzroči zelo redek, a zelo resen neželeni učinek, imenovan laktacidoza, zlasti če ledvice ne delujejo pravilno.
Glucocorticoids (given by systemic and local routes), beta 2 agonists, and diuretics have intrinsic hyperglycaemic activity. 
Glukokortikoidi (pri sistemski in lokalni uporabi), agonisti beta-2 in diuretiki imajo intrinzično hiperglikemično delovanje.
The reduction of cardiovascular death was comparable for empagliflozin 10 mg and 25 mg (see Figure 1) and confirmed by an improved overall survival (Table 
Znižanje srčno-žilne smrtnosti je bilo primerljivo za empagliflozin 10 mg in 25 mg (slika 1) in dokazano z izboljšanjem celokupnega preživetja (preglednica 9).
Increased urinary glucose excretion was maintained at the end of the 4-week treatment period, averaging approximately 78 g/day with empagliflozin 25 mg. 
Povečano izločanje glukoze z urinom se je ohranilo do konca 4-tedenskega obdobja zdravljenja in je bilo pri empagliflozinu 25 mg povprečno 78 g/dan.
Treatment with empagliflozin once daily resulted in statistically significant improvement in HbA1c, and 24 hour mean systolic and diastolic blood pressure as determined by ambulatory blood pressure monitoring (Table 10). 
Zdravljenje z empagliflozinom enkrat na dan je povzročilo statistično značilno izboljšanje HbA1c in 24-urnega povprečnega sistoličnega in diastoličnega krvnega tlaka, kot je bilo ugotovljeno z ambulantnim spremljanjem krvnega tlaka (preglednica 10).
In this analysis, AUC was estimated to be 5.82%, 10.4%, and 17.3% lower in subjects with BMI of 30, 35, and 45 kg/m2, respectively, compared to subjects with a body mass index of 25 kg/m 
V tej analizi so ocenili, da je vrednost AUC za 5,82 %, 10,4 % oz. 17,3 % nižja pri osebah z ITM 30, 35 oz. 45 kg/m2 v primerjavi z osebami z indeksom telesne mase 25 kg/m
Empagliflozin does not inhibit other glucose transporters important for glucose transport into peripheral tissues and is 5000-times more selective for SGLT2 versus SGLT1, the major transporter responsible for glucose absorption in the gut. 
Empagliflozin ne zavira drugih prenašalcev glukoze, pomembnih za prenašanje glukoze v periferna tkiva, in je 5.000-krat bolj selektiven za SGLT2 v primerjavi z SGLT1, glavnim prenašalcem, odgovornim za absorpcijo glukoze v črevesju.
• feeling sick (nausea), vomiting 
• občutek slabosti (navzea), bruhanje;